arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Immix Biopharma, Inc.

IMMX

$11.91 ▼ -0.90 (-7.06%) at close

7 Visible periods

20 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Immix Biopharma, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $392.6M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC None

FCF / Share $-0.75 ↘

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-29.44M

↓ -36.2% —

FCF / Share Free cash flow per share

$-0.75

↓ -34.2% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

FCF / Net IncomeFCF / Net Income of 0.84x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	-17.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	14.6% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	-50.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	91.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-36.2% Weak ↓ Weak Declining Year-over-year change in net income	-40.1% Weak ↑ Weak Improving Year-over-year change in net income	-87.4% Weak ↑ Weak Improving Year-over-year change in net income	66.2% Excellent Excellent Year-over-year change in net income	-2024.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-34.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	15.4% Good ↑ Good Improving Year-over-year change in free cash flow	-23.5% Weak Weak Year-over-year change in free cash flow	-23.2% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.84x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.07x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.35x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	—	-171.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-98.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-62.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	9.7% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-28.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-98.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-81.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-55.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-7.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-84.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	-163.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1187%)	-94.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-727%)	-62.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-517%)	—	24.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+62%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	-16537.12x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-7.52x Weak Weak Operating income divided by interest expense Optimal: > 5x	-4.45x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-93.93M	$-17.68M	$-17.51M	$-13.44M	$-17.64M	$-391.09K	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-0.89	$-0.76	$-0.89	$-0.59	$-6.64	—	—
Free Cash Flow per Share (USD)	$-0.75	$-0.56	$-0.66	$-0.53	$-0.43	—	—
Book Value per Share (USD)	—	$0.48	$0.82	$0.95	—	$-1.40	—
Tangible Book Value per Share (USD)	—	$0.48	$0.82	$0.95	—	$-1.40	—
Basic Weighted Avg Shares (shares)	32.97M	28.29M	17.34M	13.89M	3.67M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$91.13M	$11.51M	$16.07M	$13.62M	$17.98M	$-4.74M	—
Total Equity (USD)	—	$13.25M	$16.41M	$13.16M	—	$-4.73M	$-3.65M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$245.75K	$32.94K	$5.47K	$2.13K	$2.47K	$2.32K	—
Net Income, GAAP (USD)	$-29.44M	$-21.61M	$-15.43M	$-8.23M	$-24.38M	$-1.15M	—
Operating Cash Flow (USD)	$-23.93M	$-14.60M	$-11.37M	$-7.41M	$-1.59M	$-404.69K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 24 quarters

Immix Biopharma, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare IMMX with peers